Fresenius Kabi and the U.S. based company Cerus Corporation signed a new agreement for the production of systems for pathogen inactivation in blood components. The collaboration will help expanding access to pathogen-reduced blood components to patients. For many years, Cerus and Fresenius Kabi have collaborated regarding medical products specializing in pathogen inactivation for platelets and plasma. Since market launch of Cerus' INTERCEPT systems, more than 11 million units have been in use worldwide.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Fresenius SE & Co. KGaA published this content on 03 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 May 2022 03:32:07 UTC.